The need for diversity in clinical trials and the challenges of identifying patients who are unknown to the healthcare system complicate trial enrollment and add financial stress that may hinder the success of a study. A targeted, engineered approach to patient enrollment and diversity, using a financially calculable strategy, can ameliorate these challenges.
